Compare Stocks: XCUR, BYSI, KYNB, and ATOS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$2.56 +7.1%	$2.41	$1.70 ▼ $16.50	$23.84M	1.27	78,936 shs	70,738 shs
BYSI BeyondSpring	$0.61 -1.4%	$0.73	$0.57 ▼ $2.44	$25.31M	-0.21	586,946 shs	53,430 shs
KYNB Kyntra Bio	$5.87 -4.1%	$7.26	$5.62 ▼ $11.65	$24.78M	1.05	26,199 shs	15,928 shs
XCUR Exicure	$1.15 +5.5%	$1.26	$0.94 ▼ $9.48	$7.14M	3.64	30,852 shs	27,644 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	+7.11%	+4.49%	+1.99%	+4.92%	-83.75%
BYSI BeyondSpring	-1.43%	-12.36%	-20.59%	-52.23%	-64.52%
KYNB Kyntra Bio	-4.08%	-1.51%	-26.35%	-18.59%	+586,999,900.00%
XCUR Exicure	+5.50%	+6.48%	-17.86%	-29.01%	-77.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$2.56 +7.1%	$2.41	$1.70 ▼ $16.50	$23.84M	1.27	78,936 shs	70,738 shs
BYSI BeyondSpring	$0.61 -1.4%	$0.73	$0.57 ▼ $2.44	$25.31M	-0.21	586,946 shs	53,430 shs
KYNB Kyntra Bio	$5.87 -4.1%	$7.26	$5.62 ▼ $11.65	$24.78M	1.05	26,199 shs	15,928 shs
XCUR Exicure	$1.15 +5.5%	$1.26	$0.94 ▼ $9.48	$7.14M	3.64	30,852 shs	27,644 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	+7.11%	+4.49%	+1.99%	+4.92%	-83.75%
BYSI BeyondSpring	-1.43%	-12.36%	-20.59%	-52.23%	-64.52%
KYNB Kyntra Bio	-4.08%	-1.51%	-26.35%	-18.59%	+586,999,900.00%
XCUR Exicure	+5.50%	+6.48%	-17.86%	-29.01%	-77.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATOS Atossa Genetics	2.50	Moderate Buy	$20.33	694.27% Upside
BYSI BeyondSpring	1.00	Sell	N/A	N/A
KYNB Kyntra Bio	2.57	Moderate Buy	$36.80	526.92% Upside
XCUR Exicure	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest XCUR, BYSI, KYNB, and ATOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/13/2026	KYNB Kyntra Bio	Maxim Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$35.00
10/9/2026	KYNB Kyntra Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D+) ➝ Sell (D)
10/8/2026	BYSI BeyondSpring	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/17/2026	KYNB Kyntra Bio	Lake Street Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$41.00
9/17/2026	KYNB Kyntra Bio	Lake Street Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$41.00
9/8/2026	ATOS Atossa Genetics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/8/2026	XCUR Exicure	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/3/2026	BYSI BeyondSpring	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/1/2026	KYNB Kyntra Bio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$43.00
8/14/2026	KYNB Kyntra Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D) ➝ Sell (D+)

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$4.57 per share	N/A
BYSI BeyondSpring	$1.75M	14.26	$0.11 per share	5.42	($0.59) per share	-1.03
KYNB Kyntra Bio	$6.44M	3.69	N/A	N/A	($4.20) per share	-1.40
XCUR Exicure	$500K	15.07	N/A	N/A	$0.62 per share	1.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATOS Atossa Genetics	-$34.77M	-$3.11	N/A	N/A	N/A	N/A	-102.99%	-85.78%	11/11/2026 (Estimated)
BYSI BeyondSpring	-$1.01M	-$0.12	N/A	N/A	N/A	N/A	N/A	-28.88%	11/12/2026 (Estimated)
KYNB Kyntra Bio	$183.45M	$45.30	N/A	N/A	N/A	2,199.13%	N/A	-47.27%	N/A
XCUR Exicure	-$4.95M	-$1.32	N/A	N/A	N/A	N/A	-237.91%	-61.98%	11/12/2026 (Estimated)

Latest XCUR, BYSI, KYNB, and ATOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ATOS Atossa Genetics	-$0.86	N/A	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	BYSI BeyondSpring	-$0.54	-$0.02	+$0.52	-$0.02	$8.77 million	N/A
8/14/2026	Q2 2026	XCUR Exicure	-$18.60	-$0.18	+$18.42	-$0.18	$1.64 million	N/A
8/7/2026	Q2 2026	ATOS Atossa Genetics	-$1.02	-$0.95	+$0.07	-$0.95	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
KYNB Kyntra Bio	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATOS Atossa Genetics	N/A	5.69	5.69
BYSI BeyondSpring	N/A	0.70	0.70
KYNB Kyntra Bio	N/A	2.69	2.59
XCUR Exicure	N/A	0.56	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATOS Atossa Genetics	12.74%
BYSI BeyondSpring	40.29%
KYNB Kyntra Bio	72.71%
XCUR Exicure	42.82%

Insider Ownership

Company	Insider Ownership
ATOS Atossa Genetics	9.80%
BYSI BeyondSpring	29.31%
KYNB Kyntra Bio	4.15%
XCUR Exicure	52.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATOS Atossa Genetics	14	9.98 million	9.00 million	Optionable
BYSI BeyondSpring	44	41.12 million	29.07 million	Optionable
KYNB Kyntra Bio	570	4.05 million	3.88 million	N/A
XCUR Exicure	50	6.55 million	3.09 million	Not Optionable

XCUR, BYSI, KYNB, and ATOS Headlines

Recent News About These Companies

BioAtla (NASDAQ:BCAB) and Exicure (NASDAQ:XCUR) Head-To-Head Review

October 4, 2026 | americanbankingnews.com

Exicure stock falls 2.24 percent with Nasdaq deadline ahead

September 25, 2026 | ad-hoc-news.deA

Exicure Granted Extension By Nasdaq To Regain Compliance By Dec. '26

September 16, 2026 | rttnews.com

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement

September 16, 2026 | finance.yahoo.com

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement

September 16, 2026 | globenewswire.com

Exicure Announces Planned Issuance of Common Stock to Settle $1.0 Million Milestone Payment to GPCR Therapeutics

August 3, 2026 | quiverquant.comQ

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

August 3, 2026 | globenewswire.com

Exicure Inc (NASDAQ: XCUR) - Share Price and Research

July 15, 2026 | intelligentinvestor.com.auI

Exicure Reaches Preliminary Settlement in Derivative Lawsuits

July 9, 2026 | theglobeandmail.com

Exicure Announces Board and Committee Changes

June 30, 2026 | globenewswire.com

Exicure, Inc.: Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

June 11, 2026 | finanznachrichten.de

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

June 10, 2026 | markets.businessinsider.com

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

June 10, 2026 | globenewswire.com

Exicure Regains Nasdaq Compliance After Late Quarterly Filing

June 1, 2026 | tipranks.com

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

June 1, 2026 | globenewswire.com

Exicure delays quarterly filing, trims quarterly loss

May 15, 2026 | tipranks.com

Exicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination Therapies

April 22, 2026 | quiverquant.comQ

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

April 22, 2026 | globenewswire.com

Exicure Inc.

April 13, 2026 | barrons.com

Exicure Strengthens Leadership With New COO and Director

April 10, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR, BYSI, KYNB, and ATOS Company Descriptions

Atossa Genetics NASDAQ:ATOS

$2.56 +0.17 (+7.11%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$2.50 -0.06 (-2.34%)

As of 10/13/2026 07:59 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

BeyondSpring NASDAQ:BYSI

$0.61 -0.01 (-1.43%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$0.61 +0.01 (+0.87%)

As of 10/13/2026 07:50 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Kyntra Bio NASDAQ:KYNB

$5.87 -0.25 (-4.08%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$5.88 +0.00 (+0.09%)

As of 10/13/2026 07:30 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Exicure NASDAQ:XCUR

$1.15 +0.06 (+5.50%)

Closing price 10/13/2026 03:59 PM Eastern

Extended Trading

$1.18 +0.03 (+2.61%)

As of 10/13/2026 06:40 PM Eastern

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XCUR, BYSI, KYNB, and ATOS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XCUR, BYSI, KYNB, and ATOS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XCUR, BYSI, KYNB, and ATOS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR, BYSI, KYNB, and ATOS Company Descriptions

Atossa Genetics NASDAQ:ATOS

BeyondSpring NASDAQ:BYSI

Kyntra Bio NASDAQ:KYNB

Exicure NASDAQ:XCUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XCUR, BYSI, KYNB, and ATOS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XCUR, BYSI, KYNB, and ATOS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XCUR, BYSI, KYNB, and ATOS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR, BYSI, KYNB, and ATOS Company Descriptions

Atossa Genetics NASDAQ:ATOS

BeyondSpring NASDAQ:BYSI

Kyntra Bio NASDAQ:KYNB

Exicure NASDAQ:XCUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools